The government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...

Indian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

Corporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...

Brokerages maintain a positive outlook on select large-cap pharmaceutical, automobile, and healthcare stocks, citing strong growth prospect...

According to industry executives, the modest price hike of 0.6% that the government has allowed on essential medicines effective April 1 is...

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

Geopolitical tensions in West Asia are manageable now. However, a prolonged US-Israel war against Iran could raise costs for petrochemical-...

Sun Pharma has acquired Organon & Co for $11.75 billion. This deal provides Sun Pharma with expanded global scale and commercial reach. It ...

Sun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...

Indian markets present attractive long-term investment opportunities following recent corrections, according to Nitin Raheja of Julius Baer...

Indian equity markets face policy risks from US tariffs and West Asia conflict. These issues impact metals and pharmaceutical sectors. Expe...

France’s largest pharma company, Sanofi-Aventis, is suing India’s Sun Pharmaceuticals and Hospira’s Mayne Pharma to prevent the latter from...

Innovative pharma companies are adopting increasingly aggressive strategies to prolong the life of their product patents and keep generic p...

Indian generic pharma companies may now find it easier to challenge patents in the US. In another twist in the battle between innovators an...

Three US senators have introduced a bill in the US senate to try and prevent global pharma giants from selling cheaper copies of their own ...